Aibili Logo Association for Innovation and Biomedical Research on Light

CEC // Centre for Clinical Trials


E3 Consortium to promote and sustain collaboration and sharing of data and knowledge in the field of ophthalmic epidemiology in Europe. E3 [more info]

A single arm, open-label, multicenter study evaluating the long-term safety and tolerability of 0.5mg fingolimod (FTY720) administered orally once daily in patients with relapsing forms of multiple sclerosis (Protocol CTFY720D2399) [more info]

Randomized, open label multi-center study comparing cabazitaxel at 25 mg/m2 in combination with prednisone every 3 weeks to Docexatel in combination with prednisone in patients with metastatic castration resistant prostate cancer not pre-treated with chemotherapy (Firstana) (Protocol EFC11784) [more info]

A 24-month, phase IIIb, open-label, single arm, multicenter study assessing the efficacy and safety of an individualized, stabilization criteria-driven PRN dosing regimen with 0.5-mg ranibizumab intravitreal injections applied as monotherapy in patients with visual impairment due to macular edema secondary to central retinal vein occlusion (CRVO) (Protocol CRFB002E2401) [more info]

A 24-month, phase IIIb, open-label, randomized, active-controlled, 3-arm, multicenter study assessing the efficacy and safety of an individualized, stabilization-criteria-driven PRN dosing regimen with 0,5mg ranibizumab intravitreal injections applied as monotheraphy or with adjunctive laser photocoagulation in comparison to laser photocoagulation in patients with visual impairment due to macular edema secondary to branch vein occlusion (BRVO) (Protocol CRFB002E2402) [more info]

Prospective, Non-Intervencional, Longitudinal Cohort Study to evaluate the long-term safety of XALATAN® Treatment in Pediatric Populations (Protocol A6111143)) [more info]

Safety and IOP-Lowering Efficacy of Brinzolamide 10 mg/mL / Brimonidine 2 mg/mL Fixed Combination Eye Drops, Suspension compared to Brinzolamide 10 mg/mL Eye Drops, Suspension and Brimonidine 2 mg/mL Eye Drops, Solution in Patients with Open-Angle Glaucoma or Ocular Hypertension (Protocol C-10-040) [more info]

A phase III, randomized, double-masked 6-month clinical study to compare the efficacy and safety of the preservative-free fixed dose combination of tafluprost 0.0015% and timolol 0.5% eye drops to those of tafluprost 0.0015% and timolol 0.5% eye drops given concomitantly in patients with open angle glaucoma or ocular hypertension (Protocol 201051) [more info]

A Retrospective non-interventional study to assess the effectiveness of existing anti-vascular endothelial growth factor (anti-VEGF) treatment regimens in patients with wet age-related macular degeneration (Review) (Protocol 16378) [more info]

Study to observe the effectiveness and safety of ranibizumab through individualized patient treatment and associated outcomes (Luminous) (Protocol RFB002A2406) [more info]

Safety and Efficacy Study of ESBA1008 versus LUCENTIS® for the Treatment of Exudative Age-Related Macular Degeneration (SEE) (Protocol C-10-083) [more info]

Investigational Observational Portuguese Project with Lucentis in Age Macular Degeneration (AMD) among 50 ophthalmologic Centers for 12 months (PICO) (Protocol CRFB002APT05) [more info]

A Multicenter, Open-label, Randomized Study Comparing the Efficacy and Safety of 700 ug Dexamethasone Posterior Segment Drug Delivery System (DEX PS DDS) to Ranibizumab in Patients with Diabetic Macular Edema (POSURDEX) (Protocol 206207-024) [more info]

A 2 year Randomized, single-masked, multicenter, controlled phase IIIb trial assessing the Efficacy and safety of 0.5 mg ranibizumab in two “treat and extend” Treatment algorithms vs. 0.5 mg ranibizumab as needed in patients with macular edema and visual impairment secondary to diabetes mellitus (Protocol RETAIN - CRFB002D2304) [more info]

Data analysis regarding OCT and Color Fundus Photography in patients with Multiple Sclerosis (Protocol 028A) [more info]

C-TRACER Project nº 1 - Biomarkers of Diabetic Retinopathy Progression (Protocol 4C-2012-02) [more info]

EUROCONDOR - Neurodegeneration as an early event in the pathogenesis of Diabetic Retinopathy: A multicentric, prospective, phase II-III, double-blind randomized controlled trial to assess the efficacy of neuroprotective drugs administered topically to prevent or arrest Diabetic Retinopathy (Protocol 4C-2011-02) [more info]

Phenotypes of Nonproliferative Diabetic Retinopathy in Diabetes type 2 patients identified by Optical Coherence Tomography, Colour Fundus Photography, Fluorescein Leakage and Multifocal Electrophysiology (DIAMARKER Project: Genetic susceptibility for multi-systemic complications in diabetes type-2: New biomarkers for diagnostic and therapeutic monitoring) (Protocol 4C-2011-01) [more info]

A multicenter, patient-masked, safety extension study to evaluate the biodegradation of the brimonidine tartrate posterior segment drug delivery system (Brimo 33) (Protocol 190342-033D-00) [more info]

Identifying progression of retinal disease in eyes with NPDR in diabetes type 2 using non-invasive procedures (Protocol ECR-RET-2010-02) [more info]

Prospective, randomized, multicenter, open label phase II study to assess eficacy and safety of Lucentis® monotheraphy (ranibizumab 0.5mg intravitreal injections) compared with Lucentis® plus panretinal photocoagulation (PRP) and PRP (monotheraphy) in the treatment of patients with high risk proliferative diabetic retinopathy (Protocol CRFB002DPT04T) [more info]

Prospective, randomized, open label phase II study to assess eficacy and safety of Macugen® (pegaptanib 0.3mg intravitreal injections) plus panretinal photocoagulation (PRP) and PRP (monotheraphy) in the treatment of patient with high risk proliferative diabetic retinopathy (Protocol CC-02-2009) [more info]

Correlation phenotype/genotype in diabetic retinopathy (Protocol CEC/120) (PTDC/SAU-OSM/103226/2008) [more info]

The safety and efficacy of AL-8309B ophthalmic solution for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD) (Protocol C-08-36) [more info]

Long term (3 years) ophthalmic safety and cardiac efficacy and safety of ivabradine administered at the therapeutic recommended doses (2.5/5/7.5 mg b.i.d.) on top of anti anginal background therapy, to patients with chronic stable angina pectoris. An international, double-blind placebo controlled study (Protocol CL3-16257-067) [more info]

A 3-Year, Phase 3, Multicenter, Masked, Randomized, Sham-Controlled Trial to Assess the Safety and Efficacy of 700 µg and 350µg Dexamethasone Posterior Segment Drug Delivery System (DEX PS DDS) Applicator System in the Treatment of Patients with Diabetic Macular Edema (Protocol 206207-010) [more info]

Areas of expertise

Retina:

  • Identification of phenotypes and biomarkers of retinal disease progression
  • Testing new methods of early diagnosis of macular edema and retinal vascular disease
  • Characterisation of responders and non-responders to new available therapies of retinal disease
  • Characterization of phenotypes of diabetic retinopathy
  • Neurovascular degeneration in age-related disease

 

Glaucoma:

  • Evaluation of new drugs for glaucoma treatment

 

Other:

  • Optical Coherence Tomography in the diagnosis of neurological diseases
  • Diagnostic correlations in imaging between brain and retina
  • Eye fundus imaging as a predictor of systemic vascular disease
  • Neurovascular degeneration in age-related disease
  -   Cloud   -  Copyright © AIBILI   -   Contact Us   -   Site Map   -   Privacy Policy  -  Cookies Policy  -  Webdesign Glitz Design   -   Programming Bizview